SCHEMBL1867460

SCHEMBL1867460

NC(=O)C(O)[C@H](N)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.46
TSHR P16473 2/20 0.42
USP2 O75604 1/20 0.41
SLCO1B1 Q9Y6L6 1/20 0.41
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39
BLM P54132 2/20 0.33
ACHE P22303 2/20 0.33
PTGS1 P23219 2/20 0.33
TP53 P04637 1/20 0.33
ALOX15 P16050 1/20 0.33
PMP22 Q01453 1/20 0.33
KMT2A Q03164 1/20 0.33
NR1I2 O75469 1/20 0.33
ADRA1A P35348 1/20 0.33
LMNA P02545 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PGD P52209 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23924442 1.00 SLC7A5 (0.46) SLC7A5TSHRUSP2SLCO1B1SLC1A3
SCHEMBL2367281 1.00 SLC7A5 (0.46) SLC7A5TSHRUSP2SLCO1B1SLC1A3
SCHEMBL1867465 1.00 SLC7A5 (0.46) SLC7A5TSHRUSP2SLCO1B1SLC1A3
SCHEMBL31000531 1.00 SLC7A5 (0.46) SLC7A5TSHRUSP2SLCO1B1SLC1A3
SCHEMBL1867463 1.00 SLC7A5 (0.46) SLC7A5TSHRUSP2SLCO1B1SLC1A3
D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL5513561 0.95 TSHR (0.45) SLC7A5TSHRUSP2SLCO1B1SLC1A3
SCHEMBL5324417 0.83 USP2 (0.48) SLC7A5TSHRUSP2SLCO1B1SLC1A3
SCHEMBL5580345 0.83 USP2 (0.48) SLC7A5TSHRUSP2SLCO1B1SLC1A3
D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL2553076 0.81 TSHR (0.56) SLC7A5TSHRUSP2SLCO1B1SLC1A3
D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL5019049 0.81 TSHR (0.56) SLC7A5TSHRUSP2SLCO1B1SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552839-B2 Cyclic peptides for protection against respiratory syncytial virus VIROMETIX AG (CH) 2026-02-17 US claimed
US-20250177537-A1 AN ANTIBIOTIC, METHOD OF PREPARATION AND METHOD OF TREATMENT THEREOF NATIONAL TAIWAN UNIVERSITY (TW) 2025-06-05 US claimed
US-20240287143-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS Universität Zürich (CH) 2024-08-29 US claimed
EP-4295866-A2 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS Virometix AG (CH) 2023-12-27 EP claimed
US-20230365959-A1 METHOD FOR IMPROVING THE STABILITY OF A COMPOSITION COMPRISING A FLAVIN-DEPENDENT LACTATE DEHYDROGENASE KIKKOMAN CORPORATION (JP) 2023-11-16 US claimed
EP-3638284-B1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS VIROMETIX AG (CH) 2023-08-30 EP claimed
EP-4223884-A1 METHOD FOR IMPROVING STABILITY OF COMPOSITION CONTAINING FLAVIN-DEPENDENT LACTATE DEHYDROGENASE Kikkoman Corporation (JP) 2023-08-09 EP claimed
US-11680085-B2 Cyclic peptides for protection against respiratory syncytial virus VIROMETIX AG (CH) 2023-06-20 US claimed
US-20230101362-A1 RNA STABILIZATION TEAM MEDICAL LLC 2023-03-30 US claimed
WO-2022071417-A1 METHOD FOR IMPROVING STABILITY OF COMPOSITION CONTAINING FLAVIN-DEPENDENT LACTATE DEHYDROGENASE キッコーマン株式会社 2022-04-07 WO claimed
US-20210101941-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS Universität Zürich (CH) 2021-04-08 US claimed
EP-3638284-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS Virometix AG (CH) 2020-04-22 EP claimed
CN-110891592-A Cyclic peptides for protection against respiratory syncytial virus 维罗米蒂克斯股份公司 2020-03-17 CN claimed
WO-2018229156-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS VIROMETIX AG (CH) 2018-12-20 WO claimed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP claimed
US-20260137767-A1 LIPOPEPTIDE BUILDING BLOCKS AND SYNTHETIC VIRUS-LIKE PARTICLES VIROMETIX AG (CH) 2026-05-21 US disclosed
US-12552839-B2 Cyclic peptides for protection against respiratory syncytial virus VIROMETIX AG (CH) 2026-02-17 US disclosed
EP-0135194-A1 Azetidinones and their production Takeda Chemical Industries, Ltd. (JP) 1985-03-27 EP disclosed
EP-0073143-A2 Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides Ryan, James Walter (US) 1983-03-02 EP disclosed
EP-0048159-A2 Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents UNIVERSITY OF MIAMI (US) 1982-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11680085-B2 Cyclic peptides for protection against respiratory syncytial virus VIP, LNPEP, CSTB SLC7A5 2179/4885TSHR 2352/4885USP2 1775/4885
US-20260137767-A1 LIPOPEPTIDE BUILDING BLOCKS AND SYNTHETIC VIRUS-LIKE PARTICLES VSIR, LRBA, CD74 SLC7A5 2164/4885TSHR 2459/4885USP2 2748/4885
US-20240287143-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS VIP, QPCT, QPCTL SLC7A5 196/4885TSHR 1073/4885USP2 1530/4885
US-20210101941-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS QPCT, QPCTL, VIP SLC7A5 277/4885TSHR 2209/4885USP2 1808/4885
US-12552839-B2 Cyclic peptides for protection against respiratory syncytial virus CTH, VIP, CXCL10 SLC7A5 37/4885TSHR 1606/4885USP2 1887/4885
US-20250177537-A1 AN ANTIBIOTIC, METHOD OF PREPARATION AND METHOD OF TREATMENT THEREOF BTD, CALCR, CA6 SLC7A5 3318/4885TSHR 3789/4885USP2 3593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.